Up 290% in 12 months: Why this ASX healthcare stock is surging again today

This stock is continuing its ascent on Tuesday. But why?

| More on:
Two lab workers fist pump each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Orthocell Ltd (ASX: OCC) shares are catching the eye again on Tuesday.

In morning trade, the ASX healthcare stock is up 11% to $1.53.

This means that the regenerative medicine company's shares are now up 290% since this time last year.

To put that into context, a $5,000 investment 12 months ago would now be worth almost $20,000 today.

Why is this ASX healthcare stock jumping today?

Investors have been buying the company's shares this morning after it made another big announcement.

According to the release, Singapore's Health Sciences Authority (HSA) has granted regulatory approval for its market leading dental membrane, Striate+. This is for use in guided bone and tissue regeneration applications.

The release notes that approval in Singapore complements existing clearances in the United States, Europe/UK, Australia, New Zealand, and Canada. Management believes it will further support the robust sales growth being delivered from existing markets.

The good news for the ASX healthcare stock is that its global marketing and distribution partner for Striate+, BioHorizons, is already well established in the Singaporean market. This will help facilitate a fast transition to first sales and revenue generation from this region.

What is Striate+?

Striate+ is a sterile, resorbable collagen membrane for use in dental bone and tissue regeneration applications. This includes dental implant procedures.

It is designed to protect the bone defect from ingrowth of gingival tissue, to provide a favourable environment for osteogenesis and to assure reliable formation of high-quality bone.

Management notes that Striate+ is experiencing strong sales growth in existing markets, fuelled by overwhelmingly positive feedback from dental surgeons. It highlights that the product's unique features—such as its ease of use, ability to conform to treatment surfaces, and promotion of more efficient bone growth—have driven high adoption and contributed significantly to its success.

Approval in Singapore is a big win. That's because it is seen as a strategic regulatory market and can be used as a stepping stone to approvals in other ASEAN markets. In addition, Singapore is known for its efficiency, high standards, and state of the art medical facilities. This makes it an important destination for medical treatments and tourism in the region.

Commenting on the news, the ASX healthcare stock's CEO and managing director, Paul Anderson, said:

We are delighted to receive Singaporean regulatory approval for Striate+ in this important regional gateway market. This approval provides additional validation of Orthocell's high-quality products, manufacturing processes, and quality systems. Moreover, it enhances our ability to drive revenue growth as our distribution partner expands into global markets.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »